

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/003869-2026>

Contract

Tumour Infiltrating Lymphocyte(TIL) Therapy Hubs for Melanoma(Adults)

NHS England

F03: Contract award notice

Notice identifier: 2026/S 000-003869

Procurement identifier (OCID): ocds-h6vhtk-0595dd

Published 16 January 2026, 12:42pm

Section I: Contracting authority

I.1) Name and addresses

NHS England

Wellington House, 133-135 Waterloo Rd

London

SE1 8UG

Contact

Jessica Gaucher-Thompson

Email

jessica.gaucher-thompson@nhs.net

Country

United Kingdom

Region code

UKJ1 - Berkshire, Buckinghamshire and Oxfordshire

Internet address(es)

Main address

<https://www.england.nhs.uk/>

Buyer's address

<https://www.england.nhs.uk/>

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Tumour Infiltrating Lymphocyte(TIL) Therapy Hubs for Melanoma(Adults)

II.1.2) Main CPV code

- 85100000 - Health services

II.1.3) Type of contract

Services

II.1.4) Short description

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).

Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy Unit (ITU).

Lifileucel is being assessed via NICE's technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance:

<https://www.nice.org.uk/guidance/indevelopment/gid-ta10752>

The treatment is complex to administer, requiring surgical expertise for tumour resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.

The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:

Lot 1: London

Lot 2: East of England

Lot 3: South East
Lot 4: South West
Lot 5: Midlands
Lot 6: North East and Yorkshire
Lot 7: North West

This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.

As a result of this procurement exercise the commissioner intends to award 12 separate contracts across the 7 Lots.

The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).

II.1.6) Information about lots

This contract is divided into lots: Yes

II.1.7) Total value of the procurement (excluding VAT)

Value excluding VAT: £142,512,000

II.2) Description

II.2.1) Title

Lot 1 - London

Lot No

1

II.2.2) Additional CPV code(s)

- 85100000 - Health services

II.2.3) Place of performance

NUTS codes

- UKI - London

II.2.4) Description of the procurement

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).

Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy Unit (ITU).

Lifileucel is being assessed via NICE's technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance:

<https://www.nice.org.uk/guidance/indevelopment/gid-ta10752>

The treatment is complex to administer, requiring surgical expertise for tumour resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.

The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:

Lot 1: London

Lot 2: East of England

Lot 3: South East

Lot 4: South West

Lot 5: Midlands

Lot 6: North East and Yorkshire

Lot 7: North West

This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.

As a result of this procurement exercise, the Commissioner intends to award four separate contracts under Lot 1 - London.

The approximate lifetime value of each contract is £11,876,000, subject to the number of patients treated.

The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4

year(s)(maximum contract duration 9 years).

II.2.5) Award criteria

Quality criterion - Name: Quality & innovation / Weighting: 50

Quality criterion - Name: Value / Weighting: 2

Quality criterion - Name: Integration, Collaboration & Service Sustainability / Weighting: 21

Quality criterion - Name: Improving Access, Reducing Health Inequalities and Facilitating Choice / Weighting: 17

Quality criterion - Name: Social Value / Weighting: 10

Cost criterion - Name: Not Applicable / Weighting: 0

II.2.11) Information about options

Options: Yes

Description of options

Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s).

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

Lot 2 - East of England

Lot No

2

II.2.2) Additional CPV code(s)

- 85100000 - Health services

II.2.3) Place of performance

NUTS codes

- UKH - East of England

II.2.4) Description of the procurement

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).

Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy Unit (ITU).

Lifileucel is being assessed via NICE's technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance:

<https://www.nice.org.uk/guidance/indevelopment/gid-ta10752>

The treatment is complex to administer, requiring surgical expertise for tumour resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.

The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:

Lot 1: London

Lot 2: East of England

Lot 3: South East

Lot 4: South West

Lot 5: Midlands

Lot 6: North East and Yorkshire

Lot 7: North West

This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.

As a result of this procurement exercise, the Commissioner intends to award a contract under Lot 2 - East of England.

The approximate lifetime value of the contract is £11,876,000, subject to the number of patients treated.

The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).

II.2.5) Award criteria

Quality criterion - Name: Quality & innovation / Weighting: 50

Quality criterion - Name: Value / Weighting: 2

Quality criterion - Name: Integration, Collaboration & Service Sustainability / Weighting: 21

Quality criterion - Name: Improving Access, Reducing Health Inequalities and Facilitating Choice / Weighting: 17

Quality criterion - Name: Social Value / Weighting: 10

Cost criterion - Name: Not Applicable / Weighting: 0

II.2.11) Information about options

Options: Yes

Description of options

Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s).

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

Lot 3: South East

Lot No

3

II.2.2) Additional CPV code(s)

- 85100000 - Health services

II.2.3) Place of performance

NUTS codes

- UKJ - South East (England)

II.2.4) Description of the procurement

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).

Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy Unit (ITU).

Lifileucel is being assessed via NICE's technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance:

<https://www.nice.org.uk/guidance/indevelopment/gid-ta10752>

The treatment is complex to administer, requiring surgical expertise for tumour resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.

The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:

Lot 1: London

Lot 2: East of England

Lot 3: South East

Lot 4: South West

Lot 5: Midlands

Lot 6: North East and Yorkshire
Lot 7: North West

This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.

As a result of this procurement exercise, the Commissioner intends to award two separate contracts under Lot 3 - South East.

The approximate lifetime value of each contract is £11,876,000, subject to the number of patients treated.

The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).

II.2.5) Award criteria

Quality criterion - Name: Quality & innovation / Weighting: 50

Quality criterion - Name: Value / Weighting: 2

Quality criterion - Name: Integration, Collaboration & Service Sustainability / Weighting: 21

Quality criterion - Name: Improving Access, Reducing Health Inequalities and Facilitating Choice / Weighting: 17

Quality criterion - Name: Social Value / Weighting: 10

Cost criterion - Name: Not Applicable / Weighting: 0

II.2.11) Information about options

Options: Yes

Description of options

Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s).

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union

funds: No

II.2) Description

II.2.1) Title

Lot 4: South West

Lot No

4

II.2.2) Additional CPV code(s)

- 85100000 - Health services

II.2.3) Place of performance

NUTS codes

- UKK - South West (England)

II.2.4) Description of the procurement

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).

Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy Unit (ITU).

Lifileucel is being assessed via NICE's technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance:

<https://www.nice.org.uk/guidance/indevelopment/gid-ta10752>

The treatment is complex to administer, requiring surgical expertise for tumour resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.

The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte

(TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:

Lot 1: London

Lot 2: East of England

Lot 3: South East

Lot 4: South West

Lot 5: Midlands

Lot 6: North East and Yorkshire

Lot 7: North West

This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.

As a result of this procurement exercise, the Commissioner intends to award a contract under Lot 4 - South West.

The approximate lifetime value of the contract is £11,876,000, subject to the number of patients treated.

The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).

II.2.5) Award criteria

Quality criterion - Name: Quality & innovation / Weighting: 50

Quality criterion - Name: Value / Weighting: 2

Quality criterion - Name: Integration, Collaboration & Service Sustainability / Weighting: 21

Quality criterion - Name: Improving Access, Reducing Health Inequalities and Facilitating Choice / Weighting: 17

Quality criterion - Name: Social Value / Weighting: 10

Cost criterion - Name: Not Applicable / Weighting: 0

II.2.11) Information about options

Options: Yes

Description of options

Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s).

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

Lot 5: Midlands

Lot No

5

II.2.2) Additional CPV code(s)

- 85100000 - Health services

II.2.3) Place of performance

NUTS codes

- UKF - East Midlands (England)
- UKG - West Midlands (England)

II.2.4) Description of the procurement

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).

Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy Unit (ITU).

Lifileucel is being assessed via NICE's technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance

publication date in 2026 in line with NICE guidance:

<https://www.nice.org.uk/guidance/indevelopment/gid-ta10752>

The treatment is complex to administer, requiring surgical expertise for tumour resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.

The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:

Lot 1: London

Lot 2: East of England

Lot 3: South East

Lot 4: South West

Lot 5: Midlands

Lot 6: North East and Yorkshire

Lot 7: North West

This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.

As a result of this procurement exercise, the Commissioner intends to award a contract under Lot 5 - Midlands.

The approximate lifetime value of the contract is £11,876,000, subject to the number of patients treated.

The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).

II.2.5) Award criteria

Quality criterion - Name: Quality & innovation / Weighting: 50

Quality criterion - Name: Value / Weighting: 2

Quality criterion - Name: Integration, Collaboration & Service Sustainability / Weighting: 21

Quality criterion - Name: Improving Access, Reducing Health Inequalities and Facilitating Choice / Weighting: 17

Quality criterion - Name: Social Value / Weighting: 10

Cost criterion - Name: Not Applicable / Weighting: 0

II.2.11) Information about options

Options: Yes

Description of options

Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s).

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

Lot 6: North East & Yorkshire

Lot No

6

II.2.2) Additional CPV code(s)

- 85100000 - Health services

II.2.3) Place of performance

NUTS codes

- UKC - North East (England)
- UKE - Yorkshire and the Humber

II.2.4) Description of the procurement

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).

Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy Unit (ITU).

Lifileucel is being assessed via NICE's technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance:

<https://www.nice.org.uk/guidance/indevelopment/gid-ta10752>

The treatment is complex to administer, requiring surgical expertise for tumour resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.

The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:

Lot 1: London

Lot 2: East of England

Lot 3: South East

Lot 4: South West

Lot 5: Midlands

Lot 6: North East and Yorkshire

Lot 7: North West

This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.

As a result of this procurement exercise, the Commissioner intends to award a contract under Lot 6 - North East and Yorkshire.

The approximate lifetime value of the contract is £11,876,000, subject to the number of patients treated.

The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s) (maximum contract duration 9 years).

II.2.5) Award criteria

Quality criterion - Name: Quality & innovation / Weighting: 50

Quality criterion - Name: Value / Weighting: 2

Quality criterion - Name: Integration, Collaboration & Service Sustainability / Weighting: 21

Quality criterion - Name: Improving Access, Reducing Health Inequalities and Facilitating Choice / Weighting: 17

Quality criterion - Name: Social Value / Weighting: 10

Cost criterion - Name: Not Applicable / Weighting: 0

II.2.11) Information about options

Options: Yes

Description of options

Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s).

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

Lot 7: North West

Lot No

7

II.2.2) Additional CPV code(s)

- 85100000 - Health services

II.2.3) Place of performance

NUTS codes

- UKD - North West (England)

II.2.4) Description of the procurement

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).

Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy Unit (ITU).

Lifileucel is being assessed via NICE's technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance:

<https://www.nice.org.uk/guidance/indevelopment/gid-ta10752>

The treatment is complex to administer, requiring surgical expertise for tumour resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.

The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:

Lot 1: London

Lot 2: East of England

Lot 3: South East

Lot 4: South West

Lot 5: Midlands

Lot 6: North East and Yorkshire

Lot 7: North West

This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.

As a result of this procurement exercise, the Commissioner intends to award two separate contracts under Lot 7 - North West.

The approximate lifetime value of each contract is £11,876,000, subject to the number of patients treated.

The service is due to commence on 1st May 2025, subject to NICE guidance, for a period

of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).

II.2.5) Award criteria

Quality criterion - Name: Quality & innovation / Weighting: 50

Quality criterion - Name: Value / Weighting: 2

Quality criterion - Name: Integration, Collaboration & Service Sustainability / Weighting: 21

Quality criterion - Name: Improving Access, Reducing Health Inequalities and Facilitating Choice / Weighting: 17

Quality criterion - Name: Social Value / Weighting: 10

Cost criterion - Name: Not Applicable / Weighting: 0

II.2.11) Information about options

Options: Yes

Description of options

Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s).

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section IV. Procedure

IV.1) Description

IV.1.1) Type of procedure

Open procedure

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

IV.2) Administrative information

IV.2.1) Previous publication concerning this procedure

Notice number: [2025/S 000-054675](#)

Section V. Award of contract

A contract/lot is awarded: Yes

V.2) Award of contract

V.2.1) Date of conclusion of the contract

16 December 2025

V.2.2) Information about tenders

Number of tenders received: 4

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor

University College London Hospitals NHS Foundation Trust

London

NW1 2PG

Country

United Kingdom

NUTS code

- UKI - London

The contractor is an SME

No

V.2.4) Information on value of contract/lot (excluding VAT)

Initial estimated total value of the contract/lot: £11,876,000

Total value of the contract/lot: £11,876,000

Section V. Award of contract

A contract/lot is awarded: Yes

V.2) Award of contract

V.2.1) Date of conclusion of the contract

16 December 2025

V.2.2) Information about tenders

Number of tenders received: 4

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor

Guy's and St Thomas' NHS Foundation Trust

London

SE1 9RT

Country

United Kingdom

NUTS code

- UKI - London

The contractor is an SME

No

V.2.4) Information on value of contract/lot (excluding VAT)

Initial estimated total value of the contract/lot: £11,876,000

Total value of the contract/lot: £11,876,000

Section V. Award of contract

A contract/lot is awarded: Yes

V.2) Award of contract

V.2.1) Date of conclusion of the contract

16 December 2025

V.2.2) Information about tenders

Number of tenders received: 4

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor

Barts Health NHS Trust

London

E1 2ES

Country

United Kingdom

NUTS code

- UKI - London

The contractor is an SME

No

V.2.4) Information on value of contract/lot (excluding VAT)

Initial estimated total value of the contract/lot: £11,876,000

Total value of the contract/lot: £11,876,000

Section V. Award of contract

A contract/lot is awarded: Yes

V.2) Award of contract

V.2.1) Date of conclusion of the contract

16 December 2025

V.2.2) Information about tenders

Number of tenders received: 4

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor

The Royal Marsden NHS Foundation Trust

London

SW3 6JJ

Country

United Kingdom

NUTS code

- UKI - London

The contractor is an SME

No

V.2.4) Information on value of contract/lot (excluding VAT)

Initial estimated total value of the contract/lot: £11,876,000

Total value of the contract/lot: £11,876,000

Section V. Award of contract

A contract/lot is awarded: Yes

V.2) Award of contract

V.2.1) Date of conclusion of the contract

16 December 2025

V.2.2) Information about tenders

Number of tenders received: 1

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor

Cambridge University Hospitals NHS Foundation Trust

Cambridge

CB2 0QQ

Country

United Kingdom

NUTS code

- UKH - East of England

The contractor is an SME

No

V.2.4) Information on value of contract/lot (excluding VAT)

Initial estimated total value of the contract/lot: £11,876,000

Total value of the contract/lot: £11,876,000

Section V. Award of contract

A contract/lot is awarded: Yes

V.2) Award of contract

V.2.1) Date of conclusion of the contract

16 December 2025

V.2.2) Information about tenders

Number of tenders received: 2

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor

Oxford University Hospitals NHS FT

Oxford

OX3 9DU

Country

United Kingdom

NUTS code

- UKJ - South East (England)

The contractor is an SME

No

V.2.4) Information on value of contract/lot (excluding VAT)

Initial estimated total value of the contract/lot: £11,876,000

Total value of the contract/lot: £11,876,000

Section V. Award of contract

A contract/lot is awarded: Yes

V.2) Award of contract

V.2.1) Date of conclusion of the contract

16 December 2025

V.2.2) Information about tenders

Number of tenders received: 2

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor

University Hospitals Southampton

Southampton

SO16 6YD

Country

United Kingdom

NUTS code

- UKJ - South East (England)

The contractor is an SME

No

V.2.4) Information on value of contract/lot (excluding VAT)

Initial estimated total value of the contract/lot: £11,876,000

Total value of the contract/lot: £11,876,000

Section V. Award of contract

A contract/lot is awarded: Yes

V.2) Award of contract

V.2.1) Date of conclusion of the contract

16 December 2025

V.2.2) Information about tenders

Number of tenders received: 2

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor

University Hospitals Bristol and Weston NHS Foundation Trust

Bristol

BS1 3NU

Country

United Kingdom

NUTS code

- UKK - South West (England)

The contractor is an SME

No

V.2.4) Information on value of contract/lot (excluding VAT)

Initial estimated total value of the contract/lot: £11,876,000

Total value of the contract/lot: £11,876,000

Section V. Award of contract

A contract/lot is awarded: Yes

V.2) Award of contract

V.2.1) Date of conclusion of the contract

16 December 2025

V.2.2) Information about tenders

Number of tenders received: 3

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor

UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST

Leicester

LE1 5WW

Country

United Kingdom

NUTS code

- UKF - East Midlands (England)

The contractor is an SME

No

V.2.4) Information on value of contract/lot (excluding VAT)

Initial estimated total value of the contract/lot: £11,876,000

Total value of the contract/lot: £11,876,000

Section V. Award of contract

A contract/lot is awarded: Yes

V.2) Award of contract

V.2.1) Date of conclusion of the contract

16 December 2025

V.2.2) Information about tenders

Number of tenders received: 2

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor

The Newcastle upon Tyne Hospitals NHS Foundation Trust

Newcastle upon Tyne

NE1 4LP

Country

United Kingdom

NUTS code

- UKC - North East (England)

The contractor is an SME

No

V.2.4) Information on value of contract/lot (excluding VAT)

Initial estimated total value of the contract/lot: £11,876,000

Total value of the contract/lot: £11,876,000

Section V. Award of contract

A contract/lot is awarded: Yes

V.2) Award of contract

V.2.1) Date of conclusion of the contract

16 December 2025

V.2.2) Information about tenders

Number of tenders received: 2

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor

The Christie NHS Foundation Trust

Manchester

M204BX

Country

United Kingdom

NUTS code

- UKD - North West (England)

The contractor is an SME

No

V.2.4) Information on value of contract/lot (excluding VAT)

Initial estimated total value of the contract/lot: £11,876,000

Total value of the contract/lot: £11,876,000

Section V. Award of contract

A contract/lot is awarded: Yes

V.2) Award of contract

V.2.1) Date of conclusion of the contract

16 December 2025

V.2.2) Information about tenders

Number of tenders received: 2

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor

THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST

Wirral

CH634JY

Country

United Kingdom

NUTS code

- UKD - North West (England)

The contractor is an SME

No

V.2.4) Information on value of contract/lot (excluding VAT)

Initial estimated total value of the contract/lot: £11,876,000

Total value of the contract/lot: £11,876,000

Section VI. Complementary information

VI.3) Additional information

This is a Provider Selection Regime(PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award.

The standstill period begins on the day after the publication of this notice. Representations by providers must be made to the relevant authority by Wednesday 28th January 2026. Representations should be sent to jessica.gaucher-thompson@nhs.net. The award decision-makers are NHS England National Commissioning Group (NCG).

These contracts have not yet formally been awarded; this notice serves as an intention to award under the PSR.

The Key Criteria used for the award:

Quality & innovation: 50%

Value: 2%

Integration, Collaboration & Service Sustainability: 21%

Improving Access, Reducing Health Inequalities and Facilitating Choice: 17%

Social Value: 10%.

The rationale for selecting the provider(s) was based on them meeting all mandatory requirements and achieving the minimum quality threshold set out in the procurement documentation. This decision has been made as per NHS England governance processes, by the National Commissioning Group on 16th December 2025. No conflicts of Interest were identified amongst decision-makers.

VI.4) Procedures for review

VI.4.1) Review body

NHS Arden and Greater East Midlands Commissioning Support Unit

Cardinal Square, 10 Nottingham Road

Derby

DE1 3QT

Country

United Kingdom

Internet address

<https://www.ardengemcsu.nhs.uk/>